

INSTITUTIONAL RESEARCH Biotechnology UPDATE REPORT

Member FINRA/SIPC

Toll-Free: 866-928-0928 • www.DawsonJames.com • 101 North Federal Highway - Suite 600 • Boca Raton, FL 33432

Can-Fite BioPharma Ltd. (NYSE/CANF)

BUY: Valuation Rolls Forward – New Shares Registered

Can-Fite announced Armistice Capital Masters Fund, Ltd. registers shares ~1.2B ordinary shares (represented by 4.1M ADS) for holders. At the same time, we roll our valuation metrics out a year (YE 2024). Our valuation remains unchanged. We have had many calls with the management teams of the Israeli based companies we follow. The Israeli's have a great capacity to adapt as personnel (reservists) are now active and their duties are being covered by the folks remaining at the company. On a personal note, our thoughts and prayers are with Israel and the hostages being held by terrorists that they may be returned home.

Investment Highlights:

Namodenoson: Exploratory Phase II Pancreatic Cancer Study— The study is planned as a multicenter open-label trial in patients with advanced pancreatic adenocarcinoma whose disease has progressed on at least 1st-line therapy or who refuse standard treatment. The trial will evaluate the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson in this population. Patients will receive oral Namodenoson 25 mg administered twice daily for consecutive 28-day cycles. Patients will be evaluated regularly for safety. Approximately 20 evaluable patients are to be enrolled. The primary objective of this trial is to characterize the safety profile of Namodenoson and the secondary objective is to evaluate the clinical activity as determined by the Objective Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1), Progression-Free Survival (PFS), Disease Control Rate (DCR), Duration of Response (DoR), and Overall Survival (OS). The study will be conducted by Salomon Stemmer, a leading key opinion leader, at the Institute of Oncology, Rabin Medical Center, Israel.

Namodenoson: Pivotal Phase III Advanced Liver Cancer Study continues its enrollment in patients with advanced hepatocellular carcinoma (HCC) and underlying Child Pugh B7 (CPB7) who have not responded to one or two other lines of therapy. The primary endpoint is overall survival. An interim analysis will be conducted by an Independent Data Monitoring Committee (IDMC) after 50% of the planned 450 patients are enrolled and treated.

Valuation. We evaluate Piclidenoson in Psoriasis, Namodenoson in HCC, and NAFLD, we do not include pancreatic cancer (yet). We apply a probability of success factor in these patient-based models. These metrics then flow into our valuation models. For Can-Fite, we use a 30% discount rate (in addition to the risk rate), as Can-Fite is not yet profitable, and most of the products are still dependent on the outcome of the clinical trials. Our valuation conclusion is an equally weighted average of our FCFF, EPS, and sum-of-the-parts analysis. We use a projected fully diluted end-year share count and assume multiple raises which results in our model.

Risks to our thesis include the following: (1) commercial; (2) regulatory; (3) clinical; (4) manufacturing; (5) financial; (6) liability; and (7) intellectual property.

December 13, 2023 Jason Kolbert Managing Director & Senior Analyst jkolbert@dawsonjames.com



ource: Can-Fite tock Data 2-Week Range \$1.52 hares Outstanding (mil.) Market Capitalization (mil.) nterprise Value (mil.)	- \$7.60 1,359.8 \$2,746.9 \$0.9 0.0% \$45.18
2-Week Range \$1.52 hares Outstanding (mil.) larket Capitalization (mil.)	1,359.8 \$2,746.9 \$0.9 0.0%
hares Outstanding (mil.) larket Capitalization (mil.)	1,359.8 \$2,746.9 \$0.9 0.0%
larket Capitalization (mil.)	\$2,746.9 \$0.9 0.0%
	\$0.9 0.0%
nterprise Value (mil.)	0.0%
ebt to Capital	\$45.18
ook Value/Share	Q40.10
rice/Book	3.7
verage Three Months Trading Volume	≘(M) 0.0
sider Ownership	
stitutional Ownership	1.6%
hort interest (mil.)	0.0%
ividend / Yield	\$0.00/0.0%
Can-Fite BioPharma Ltd. Sponsored	ADR (CANF-US)
Volume (Thousands)	Price (USD)
Volume — Can-Fite BioPharma Lt	d. Sponsored ADR
	7
	6





Exhibit 1. Income Statement

Can-Fite Biopharma.: Income Statement (\$000)																
: YE December 31	2019A	2020A	2021A	2022A	1Q23A	2Q23A	3Q23A	4Q23E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Revenue:	2,032	763	853	810												
Piclidenoson (CF-101), Rheumatoid Arthritis U.S.	_,			-	-	-	-	-	-	-	-	-	-	-	-	-
Piclidenoson (CF-101), Rheumatoid Arthritis EU				-	-	-	-	-	-	-	-	-	-	-	-	
Piclidenoson (CF-101), Psoriasis U.S.				-	-	-	-	-	-	-	-		53,044	110,375	172,251	238,9
Piclidenoson (CF-101), Psoriasis EU													51,199	106,536	166,260	230,6
Vamodenoson HCC U.S.											8.261	17,189	26,825	37,212	48,394	60,4
Vamodenoson HCC EU					_		_				11,543	24,019	37,484	51,998	67,624	84,4
Vamodenoson NASH/NAFLD U.S.				-	-	-	-	-	_	-	11,545	24,013	57,404	51,550	07,024	04,4
Vamodenoson NASH/NAFLD U.S.				-	-	-	-	-	-	-	-	-	-	-	-	-
Fotal Product Sales	2.032	763	853	810	-	-	-	-	-	-	19.804	41.208	168.553	306.121	454.529	614.4
	2,032	763	600	810	-	-		-	-	-	19,604	41,208	100,000	306,121	454,529	614,4
lilestone From Gebro Holdings																
Piclidenoson (CF-101), Rheumatoid Arthritis U.S.																
Royalty Rate from Global Partnership																
iclidenoson (CF-101), Rheumatoid Arthritis EU																
Royalty Rate from Global Partnership										-			_	_	_	
iclidenoson (CF-101), Psoriasis U.S.										-	-		13,261	27,594	43,063	59,7
Royalty Rate from Global Partnership										_			26%	26%	26%	2
Piclidenoson (CF-101), Psoriasis EU										-	-		13,261	27,594	43,063	59,7
Royalty Rate from Global Partnership													26%	26%	26%	2
amodenoson HCC U.S.											2,065	4,297	6,706	9,303	12,099	15,1
Royalty Rate from Global Partnership											25%	25%	25%	25%	25%	2
lamodenoson HCC EU										-	2,886	6,485	10,121	14,040	18,258	22,7
oyalty Rate from Global Partnership											25%	27%	27%	27%	27%	· 2
amodenoson NASH/NAFLD U.S.										· .				-		
loyalty Rate from Global Partnership																
lamodenoson NASH/NAFLD EU										· .	· .				·	
Royalty Rate from Global Partnership				-					-	-	-	-	-	-	-	
Total royalties, collaborative revenue																
Total Revenue	2,032	763	853	810	196	196	196	-	588		4,951	10,782	43,349	78,530	116,482	157,3
	2,002	100	000	010	130	150	130		000		4,501	10,702	40,040	10,000	110,402	107,0
xpenses:																
artnership Costs including COGS	-	-	-	-	-	-	-	-	-	-	990	2,060	8,428	15,306	22,726	30,7
	COGS			0%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	5%	
Research and Development	10,976	11,951	9,850	7,763	2,061	1,356	1,299	1,200	5,916	6,034	6,155	6,278	6,404	6,532	6,662	6,7
	%R&D	11,551	3,030	1,105	2,001	1,550	1,235	1,200	3,310	0,034	0,133	0,270	0,404	0,552	0,002	0,7
General and Administrative	3,059	2,951	3,845	3,143	847	624	762	750	2,983	3,132	3,289	3,453	3,626	3,807	3.998	4,1
	3,059 SG&A	2,951	3,645	3,143	047	624	762	750	2,903	3,132	3,209	3,453	3,020	3,007	3,990	4,1
%	SG&A															
otal Expenses	14,035	14,902	13,695	10,906	2,908	1,980	1,473	1,950	8,899	9,166	10,434	11,792	18,457	25,645	33,386	41,7
perating Income (Loss)	(12,003)	(14,139)	(12,842)	(10,096)	(2,712)	(1,784)	(1,277)	(1,950)	(7,723)	(9,166)	(5,483)	(1,009)	24,892	52,885	83,096	115,6
inance expenses	693															
inance income	3,109	(304)	227	(77)	162	114	103									
				_						_	L					
otal Other Income	2,416	(304)		(77)	162	114	103	-	r -	-	r -	r -	r -	-	· -	
retax Income	(9,587)	(13,835)	(12,615)	(10,173)	(2,550)	(1,670)	(1,174)	(1,950)	(7,723)	(9,166)	(5,483)	(1,009)	24,892	52,885	83,096	115,6
axes on income										-	L	L	L			
axes		(715)	(2,590)							(458)	(439)	-	1,245	5,289	13,295	28,9
emeasurement loss from defined benefit plans																
ax Rate										0%	0%	0%	5%	10%	16%	2
GAAP Net Income (Loss)	(9.587)	(14,443)	(12,615)	(10,173)	(2.550)	(1.670)	(1,174)	(1,950)	(7,723)	(9,166)			23.648	47,597	69.801	86.7
	(0,001)	(,1.10)	(,0.10)	(10,110)	(1,000)	(1,010)	(,	(1,000)	(1,120)	(0,100)	(0,100)	(1,000)				
	(1.77)	(1.02)	(0.58)	(0.28)	(0.31)	(0.20)	(0.09)	(0.16)	(0.75)	(0.54)	(0.30)	(0.05)	1.27	2.55	3.72	4
AAP-EPS	(1.77)															
	(1.35)	(0.48)	(0.33)	(0.13)	(0.43)	(0.28)	(0.09)	(0.16)	(0.84)	(0.51)	(0.27)	(0.05)	1.17	2.34	3.42	4
SAAP-EPS SAAP-EPS (Dil) Vgtd Avg ADR Shrs (Bas) - '000s		(0.48) 17,191	(0.33) 21,416	(0.13) 37,202	(0.43) 8,298	(0.28) 8,298	(0.09) 12,358	(0.16) 12,370	(0.84) 10,331	(0.51) 16,906	(0.27) 18,478	(0.05) 18,552	1.17 18,626	2.34 18,701	3.42 18,776	4. 18,8

Source: Dawson James Securities estimates, company reports



Risk Analysis

In addition to the typical risks associated with development-stage specialty pharmaceutical companies, potential risks specific to Can-Fite are as follows:

Financial risk. The Company may need to raise capital in the marketplace, and there can be no assurances that the Company will be able to successfully raise capital and/or do so on favorable terms.

Clinical and regulatory risk. Lead products must start and complete clinical trials. Trials may not produce results sufficient for regulatory approval.


Partnership risk. Can-Fite may seek partnerships for clinical development support and commercialization. We have no specific knowledge of any discussions with possible partners today, and there can be no assurances that the Company will be able to secure a favorable partnership.

Commercial risk. There are no assurances that the Company will be able to secure favorable pricing, commercially launch products, and achieve significant market share to become profitable.

Legal and intellectual property risk. The Company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and or that the Company may infringe on third parties' patents.

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years:

Update – Buy – March 5, 2020 – Price Target \$9 Update – Buy – April 13, 2020 – Price Target \$9 Update – Buy – April 20, 2020 – Price Target \$9 Update – Buy – May 19, 2020 – Price Target \$9 Update – Buy – June 1, 2020 – Price Target \$9 PT Change – Buy – June 9, 2020 – Price Target \$9 PT Change – Buy – June 10, 2020 – Price Target lowered from \$9 to \$7.0 Update – Buy – June 30, 2020 – Price Target \$7 Update – Buy – June 30, 2020 – Price Target \$7 Update – Buy – July 30, 2020 – Price Target \$7 Update – Buy – August 31, 2020 – Price Target \$7 PT Change – Buy – October 6, 2020 – Price Target \$5 Update – Buy – November 16, 2020 – Price Target \$5 Update – Buy – December 1, 2020 – Price Target \$5 Update – Buy – January 25, 2021 – Price Target \$5



Update - Buy - February 23, 2021 - Price Target \$5 Update - Buy - March 5, 2021 - Price Target \$5 Update - Buy - March 29, 2021 - Price Target \$5 Update - Buy - April 22, 2021 - Price Target \$5 Update - Buy - April 29, 2021 - Price Target \$5 Update - Buy - May 27, 2021 - Price Target \$5 Update - Buy - June 4, 2021 - Price Target \$5 Update - Buy - July 8, 2021 - Price Target \$5 Update - Buy - August 27, 2021 - Price Target \$5 Update - Buy - December 7, 2021 - Price Target \$5 Update – Buy – December 20, 2021 – Price Target \$5 Update - Buy - January 5, 2022 - Price Target \$5 Update - Buy - January 31, 2022 - Price Target \$5 Update – Buy – March 8, 2022 – Price Target \$5 Update – Buy – March 25, 2022 – Price Target \$5 Update - Buy - May 26, 2022 - Price Target \$5 Update - Buy - June 29, 2022 - Price Target \$5 Update - Buy - July 11, 2022 - Price Target \$5 Update - Buy - August 22, 2022 - Price Target \$5 Update - Buy - August 23, 2022 - Price Target \$5 Update - Buy - September 1, 2022 - Price Target \$5 Update - Buy - September 12, 2022 - Price Target \$5 Update - Buy - September 21, 2022 - Price Target \$5 Update - Buy - October 14, 2022 - Price Target \$5 Update - Buy - October 25, 2022 - Price Target \$5 Update - Buy - November 29, 2022 - Price Target \$5 Price Target Change - Buy - December 12, 2022 - Price Target \$8 Update - Buy - December 28, 2022 - Price Target \$8 Rating Change - Buy to Neutral - January 3, 2023 - Price Target NA Update - Neutral - January 12, 2023 - Price Target NA Update - Neutral - March 14, 2023 - Price Target NA Update - Neutral - April 10, 2023 - Price Target NA Rating Change - Neutral to Buy - May 1, 2023 - Price Target \$6.0 Update - Buy - May 30, 2023 - Price Target \$6.0 Update – Buy – June 1, 2023 – Price Target \$6.0 Update - Buy - June 15, 2023 - Price Target \$6.0 Update – Buy – June 29, 2023 – Price Target \$6.0 Update – Buy – July 18, 2023 – Price Target \$6.0 Update – Buy – August 31, 2023 – Price Target \$6.0 Update - Buy - November 30, 2023 - Price Target \$6.0 Update – Buy – December 4, 2023 – Price Target \$6.0

Update – Buy – December 13, 2023 – Price Target \$6.0

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject Company (s). The Firm has NOT engaged in investment banking relationships with CANF in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject Company (s). The Firm has not received other compensation from the subject Company (s) in the last 12 months for services unrelated to managing or co-managing a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the Company (s) in this report and may increase or decrease holdings in the future. As of November 14, 2023, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the Company (s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad

Can-Fite Page 4 of 5



pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about risks can be found in the "RISK ANALYSIS" section of this report.

The securities of the Company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy**: the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral**: the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell**: the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

	Company Coverage			
				% of
Ratings Distribution	# of Companies	% of Total	# of Companies	Totals
Market Outperform (Buy)	21	61.76%	3	8.80%
Market Perform (Neutral)	13	38.24%	2	5.90%
Market Underperform (Sell)	0	0%	0	0.00%
Total	34	100%	5	14.70%

Current as of 14-Nov-23

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.